Exchange: NASDAQ·Updated 01:40 AM EDT
OTLK logo

OTLK Outlook Therapeutics Inc

$0.6235
$0.0004
(0.06%)
Overnight
Prev Close $0.6231
Reported EarningsAug 14
Mkt Cap$154.2M
Vol3.58M

About OTLK

Outlook Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of ONS-5010/LYTENAVA. Its pipeline includes unmet patient needs, repackaged IV bevacizumab, and anti-VEGF. The company was founded by Pankaj Mohan on January 5, 2010 and is headquartered in Iselin, NJ.
24

Extremely Bearish Sentiment

How do you feel about OTLK?

Advertisement|Remove ads.